Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Net Margin (2016 - 2025)

KalVista Pharmaceuticals' Net Margin history spans 7 years, with the latest figure at 224.74% for Q2 2020.

  • On a quarterly basis, Net Margin rose 14707.0% to 224.74% in Q2 2020 year-over-year; TTM through Jul 2024 was 741.41%, a N/A change, with the full-year FY2025 number at 834.62%, down 72930.0% from a year prior.
  • Net Margin hit 224.74% in Q2 2020 for KalVista Pharmaceuticals, up from 783.26% in the prior quarter.
  • Over the last five years, Net Margin for KALV hit a ceiling of 13.57% in Q2 2018 and a floor of 94342.86% in Q1 2016.
  • Historically, Net Margin has averaged 6583.21% across 5 years, with a median of 371.8% in 2019.
  • Biggest five-year swings in Net Margin: crashed -2028571bps in 2016 and later surged 494721bps in 2018.
  • Tracing KALV's Net Margin over 5 years: stood at 2152.79% in 2016, then soared by 79bps to 442.41% in 2017, then soared by 81bps to 83.85% in 2018, then plummeted by -167bps to 224.08% in 2019, then fell by 0bps to 224.74% in 2020.
  • Business Quant data shows Net Margin for KALV at 224.74% in Q2 2020, 783.26% in Q1 2020, and 224.08% in Q4 2019.